MREO NASDAQ
Mereo BioPharma Group plc
1W: +2.6%
1M: +42.1%
3M: +20.0%
YTD: -25.6%
1Y: -81.5%
3Y: -71.9%
5Y: -84.2%
$0.38
+0.01 (+3.52%)
Weekly Expected Move ±14.3%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$500K
+0.0% ▲
Gross Profit
$367K
+0.0% ▲
Operating Income
-$41M
+14.5% ▲
Net Income
-$42M
+3.2% ▲
EPS (Diluted)
$-0.26
+11.1% ▲
EBITDA
-$39M
+3.5% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $49M | $0 | $10M | $0 | $500K |
| YoY Growth | +9178.4% | -95.9% | +563.6% | -100.0% | +0.0% |
| Cost of Revenue | $24M | -$257K | $3M | $0 | $133K |
| Gross Profit | $25M | $257K | $7M | $0 | $367K |
| Gross Margin | 50.9% | — | 74.3% | — | 73.4% |
| R&D Expenses | $32M | $31M | $17M | $21M | $18M |
| SG&A Expenses | $22M | $23M | $18M | $26M | $23M |
| Operating Expenses | $53M | $54M | $36M | $47M | $41M |
| Operating Income | -$28M | -$54M | -$28M | -$47M | -$41M |
| Operating Margin | -57.4% | — | -284.2% | — | -8100.3% |
| Interest Expense | $5M | $3M | $3M | $1M | $256K |
| Income Before Tax | $19M | -$44M | -$30M | -$43M | -$44M |
| Tax Expense | $2M | -$2M | -$532K | $0 | -$2M |
| Net Income | $17M | -$42M | -$29M | -$43M | -$42M |
| Net Margin | 34.9% | — | -294.7% | — | -8375.6% |
| EPS (Diluted) | $749.65 | $-1750.35 | $-1100.22 | $-0.29 | $-0.26 |
| EBITDA | $25M | -$40M | -$26M | -$41M | -$39M |
| Shares Outstanding | 117M | 121M | 132M | 148M | 159M |